Capricor Therapeutics (CAPR) Retained Earnings (2010 - 2026)

Capricor Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$253727.0 for Q1 2026.

• On a quarterly basis, Retained Earnings fell 114.0% year-over-year to -$253727.0 in Q1 2026; TTM through Mar 2026 was -$253727.0, a 114.0% decrease from a year earlier, with the FY2025 full-year figure at $283154.0, down 72.43% from the prior year.
• Retained Earnings retreated to -$253727.0 in Q1 2026 per CAPR's latest filing, from $283154.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $1.8 million in Q1 2025 and bottomed at -$274.7 million in Q3 2025.
• The 5-year median for Retained Earnings is -$123.0 million (2022), against an average of -$100.8 million.
• Biggest YoY gain for Retained Earnings was 335.5% in 2024; the steepest drop was 170333.5% in 2024.
• Year by year, Retained Earnings stood at -$137.1 million in 2022, then surged by 100.17% to $235813.0 in 2023, then surged by 335.5% to $1.0 million in 2024, then slumped by 72.43% to $283154.0 in 2025, then plunged by 189.61% to -$253727.0 in 2026.
• Per Business Quant, the three latest CAPR Retained Earnings figures stand at -$253727.0 (Q1 2026), $283154.0 (Q4 2025), and -$274.7 million (Q3 2025).